SABCS 2022: First-Line Ribociclib Plus Endocrine Therapy in Patients With Aggressive Breast Cancer
Posted: 12/19/2022 | By: Melissa E. Fryman, MS

The primary results from the RIGHT Choice trial involving premenopausal patients with aggressive HR-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy vs physician’s choice of combination chemotherapy were presented at the 2022 San Antonio Breast Cancer Symposium (Abstract GS1-10).

Question 1 of 5

Which of the following best fits the definition of visceral crisis?

Choose 1